CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Oncology is one of the most rapidly evolving fields in medicine. Results presented at major cancer conferences from a myriad of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, medical oncologists and hematologists must be well informed  of these advances.
  
  To bridge the gap between research and clinical practice, this issue of Cancer Conference Update features one-on-one discussions with Drs Wolchok, Leonard, Oh, Saltz, Kim, Giralt, Gralow, O’Brien and Karlan about the integration of key data sets presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois into the practical management of patients diagnosed with a number of solid tumors and hematologic cancers.
  
  LEARNING OBJECTIVES

  • Incorporate emerging clinical trial data on novel antibody therapy into treatment decision-making for patients with advanced melanoma.
  • Assess the practical implications of emerging research examining the use of biologic agents, novel androgen-targeted agents and bone-directed therapies for castration-resistant, metastatic prostate cancer.
  • Incorporate emerging research information on the use of novel schedules, regimens and agents into the systemic treatment of various hematologic cancers.
  • Develop a therapeutic algorithm for the use of mTOR and VEGF inhibitors in the management of metastatic renal cell carcinoma.
  • Apply pivotal clinical trial results with cytotoxic, molecular-targeted and locally directed therapies to the multimodality management of diverse forms of gastrointestinal cancer.
  • Employ individualized patient assessment to tailor the use of cytotoxic, biologic and/or small-molecule targeted therapy for non-small cell lung cancer.
  • Recognize the emerging contribution of induction chemotherapy and biologic agents to standard chemoradiation therapy approaches for head and neck cancer.
  • Communicate the benefits and risks of anti-angiogenic therapy, novel targeted agents, anti-HER2 treatments and PARP inhibitors to appropriately selected patients with advanced breast cancer.
  • Assess the relevance of emerging research information on PARP inhibitors and anti-angiogenic therapies to current protocol and nonprotocol management of advanced ovarian cancer.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains an audio component. The participant should review the CME information and listen to the CDs.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — Dr O’Brien had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Wolchok — Advisory Committee and Consulting Agreement: Bristol-Myers Squibb Company. Dr Leonard — Consulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr Oh — Advisory Committee: Sanofi; Consulting Agreements: Dendreon Corporation, Pfizer Inc. Dr Saltz — Advisory Committee: EMD Serono Inc, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genomic Health Inc, Genzyme Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OSI Oncology; Paid Research: Amgen Inc, Merck and Company Inc. Dr Kim — Advisory Committee: Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Onyx Pharmaceuticals Inc; Paid Research: Genentech BioOncology, Lilly USA LLC, OSI Pharmaceuticals Inc. Dr Giralt — Advisory Committee and Speakers Bureau: Amgen Inc, Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.  Dr Gralow — Paid Research: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc. Dr Karlan — Paid Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company and Novartis Pharmaceuticals Corporation.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: September 2011
  Expiration date: September 2012